Distribution · Türkiye · Announced 16 Jun 2026

Türk İlaç ve Serum → Pharexpo

Borsa İstanbul-listed Türk İlaç ve Serum appointed wholesaler Pharexpo as exclusive marketer and distributor of all its own-manufactured medicines in Türkiye's pharmacy channel, replacing a January 2026 exclusivity with Ceo Pharma.

Parties: Türk İlaç ve Serum Sanayi (Turkey) → Pharexpo (Turkey)

Deal type
Distribution
Value
Undisclosed
Territory
Turkey (pharmacy channel)
Therapeutic area
Multi-therapy
Asset
Türk İlaç portfolio
Announced
16 Jun 2026

Our analysis

Why this matters

On 16 June 2026, Türk İlaç ve Serum Sanayi A.Ş. (Borsa İstanbul: TRILC) disclosed via KAP an exclusivity agreement with Pharexpo İlaç Ecza Deposu, a Turkish pharmaceutical wholesaler. Pharexpo will market and distribute all medicines manufactured at Türk İlaç's own facilities in the pharmacy channel. The company expects the deal to raise its pharmacy-market share and to have a positive effect on revenue and EBITDA. No value, duration or volume targets were disclosed.

The same day, Türk İlaç terminated an earlier exclusivity agreement for the pharmacy market with Ceo Pharma İlaç Ecza Deposu, which had been signed on 6 January 2026. The termination date itself was not given.

The full analysis is free to read with a work email on this page.

Source: Paratic (citing KAP disclosure); Borsa Gündem; YatırımX

Latest deals

All Türkiye deals → · All distribution deals → · Browse all emerging-market pharma deals →